Company
Hypera SA
Headquarters: Sao Paulo, SP, Brazil
Employees: 9,000
Market Cap
R$11.65 Billion
BRL as of Jan. 1, 2025
US$1.89 Billion
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | R$8.00 B |
| EBITDA | R$2.72 B |
| Gross Profit TTM | R$4.95 B |
| Profit Margin | 21.14% |
| Operating Margin | 29.58% |
| Quarterly Revenue Growth | -1.90% |
Stocks & Indices
Hypera SA has the following listings and related stock indices.
Stock: Bovespa: HYPE3 wb_incandescent
Stock: XSTU: HM6A wb_incandescent
Stock: OTC: HYPMY wb_incandescent